Pregabalin and Nortriptyline Tablet Uses: A Complete Guide for Patients and Neurologists

Introduction: Why Nerve Pain Doesn't Respond to Regular Painkillers — and What Does Work

There is a moment most neuropathic pain patients remember clearly: the moment they realised that the paracetamol or ibuprofen that relieves their headache or muscle soreness is doing absolutely nothing for the burning, shooting pain in their feet, the electric-shock sensations running down their legs, or the relentless tingling in their hands. They may have escalated to stronger over-the-counter painkillers. The pain didn't budge.

This is not a matter of dose or willpower. It is a fundamental difference in the biological mechanism of nerve pain versus the types of pain conventional analgesics are designed to treat. NSAIDs and paracetamol address pain driven by tissue inflammation and prostaglandin sensitisation. Neuropathic pain — pain generated by damage or dysfunction within the nervous system itself — involves an entirely different set of molecular players: calcium channel overactivity, dysregulated neurotransmitter release, and failure of the brain's own pain-suppression circuits. These mechanisms do not respond to prostaglandin-blocking drugs because prostaglandins are not the primary driver.

This is the clinical gap that the combination of pregabalin and nortriptyline fills — targeting nerve pain at two distinct points in its generation and amplification pathway, through two molecules that work through completely different mechanisms and therefore complement rather than simply duplicate each other.

This guide explains what pregabalin and nortriptyline tablets are, how each ingredient works, what conditions they treat, how to take them correctly, what side effects to expect, and what neurologists and patients need to know for safe and effective long-term nerve pain management.

What Are Pregabalin and Nortriptyline Tablets?

Pregabalin and nortriptyline tablets are a fixed-dose combination (FDC) oral formulation for neuropathic pain, containing:

• Pregabalin 75mg — a gabapentinoid that reduces the abnormal electrical hyperactivity of damaged nerve fibres by binding to voltage-gated calcium channels on presynaptic nerve terminals
• Nortriptyline 10mg — a tricyclic antidepressant used here at a sub-antidepressant, pain-modulating dose that strengthens the brain and spinal cord's descending inhibitory pain pathways by prolonging the availability of serotonin and noradrenaline at key synaptic sites

The tablet is film-coated and packed in a 10×10 Alu-Alu blister — full aluminium foil on both lid and base — protecting pregabalin from moisture and nortriptyline from light degradation throughout the product's 24-month shelf life.

This is a prescription-only medicine used in the management of chronic neuropathic pain conditions — conditions where the nervous system itself has become the source of pain signals rather than a damaged peripheral tissue.

Understanding Neuropathic Pain — Why It Is Different

Before understanding how this combination works, it is worth understanding why neuropathic pain is mechanistically distinct from the pain patients are more familiar with.

Nociceptive pain — the pain from a cut, a bruise, an inflamed joint — is driven by tissue damage activating peripheral pain receptors (nociceptors) that send signals to the brain. The nerve fibres are the messenger, not the problem. Anti-inflammatory drugs reduce the tissue signal; analgesics dampen the message in transit.

Neuropathic pain occurs when the nerve fibres themselves are damaged, compressed, or chronically irritated. Damaged nerves become electrically unstable — they begin firing spontaneous, unregulated electrical signals without any peripheral stimulus. The brain receives pain signals from nerves that have nothing to report except their own dysfunction. This produces the characteristic qualities of neuropathic pain that patients describe: burning, electric-shock-like sensations, shooting or stabbing pain, hypersensitivity to touch (allodynia — where even a bedsheet or gentle pressure is painful), and tingling or pins-and-needles that persist without any obvious external cause.

This spontaneous, stimulus-independent nerve firing does not originate in tissue inflammation — which is why anti-inflammatory drugs are ineffective. The treatment must target the neural mechanisms driving the abnormal electrical activity.

India's neuropathic pain burden is particularly large — driven primarily by the country's epidemic of type 2 diabetes, which causes diabetic peripheral neuropathy in approximately 30–50% of diabetic patients over time. Post-herpetic neuralgia following shingles is common in an older population with high historical varicella exposure. Lumbar disc disease-related radiculopathy affects millions of working-age adults. And fibromyalgia, long underdiagnosed in India, is increasingly recognised as a significant cause of widespread chronic pain in adult women. This combination tablet addresses all of these presentations through its dual neuro-targeted mechanism.

How Each Ingredient Works — The Two-Pathway Mechanism

Pregabalin — Quieting the Overactive Nerve

Pregabalin belongs to the gabapentinoid class — named for its structural relationship to GABA (gamma-aminobutyric acid), though its primary mechanism is not direct GABA receptor activation. Instead, pregabalin binds with high affinity to the α₂-δ (alpha-2-delta) subunit of voltage-gated calcium channels — channels that are abundantly expressed on the presynaptic terminals of neurons involved in pain signal transmission, particularly in the dorsal horn of the spinal cord and in peripheral sensory nerve endings.

Here is what happens in a damaged nerve: the injury causes these voltage-gated calcium channels to become abnormally overexpressed and overactive. Excessive calcium flows into the nerve terminal with each electrical impulse — far more than normal function requires. This calcium flood triggers the release of excitatory neurotransmitters: glutamate (the primary excitatory neurotransmitter amplifying pain signals at the spinal cord level), substance P (a neuropeptide critically involved in pain sensitisation), and noradrenaline. This sustained release of excitatory mediators is what sustains the chronic, spontaneous pain signals that neuropathic pain patients experience.

Pregabalin's binding to the α₂-δ subunit reduces the efficiency of calcium channel opening — reducing calcium influx without fully blocking the channel. The result: fewer excitatory neurotransmitters released per impulse, reduced spontaneous nerve firing, and a progressive reduction in the abnormal pain signal generation at the source of nerve injury.

Clinically, patients experience this as:

• Reduction in the burning, shooting, or electric sensations driven by spontaneous nerve firing
• Reduced hypersensitivity to touch and temperature — the allodynia that makes even light contact painful
• Improvement in the sleep disruption caused by nocturnal nerve pain (the pain that worsens at night due to reduced competing sensory input)

Pregabalin's absorption is linear and predictable — it is not metabolised by the liver and is excreted unchanged in the urine, making its pharmacokinetics straightforward to manage. It reaches therapeutic plasma levels within 1–2 hours of an oral dose and is effective twice or three times daily.

Nortriptyline — Amplifying the Brain's Own Pain Filter

Nortriptyline is a tricyclic antidepressant (TCA) — a drug class developed in the 1950s primarily for depression management. At the 10mg dose used in this combination, nortriptyline's contribution has almost nothing to do with its antidepressant action — which typically requires 50–150mg doses sustained over weeks. At 10mg, the relevant mechanism is its effect on the descending inhibitory pain pathway.

The brain and spinal cord have a built-in pain-suppression system — a set of neuronal pathways that descend from the brainstem (specifically the periaqueductal grey and rostral ventromedial medulla) down through the spinal cord to the dorsal horn, where incoming pain signals from the periphery first arrive. This system uses serotonin and noradrenaline as its neurotransmitters — releasing them at dorsal horn synapses to reduce the amplitude of incoming pain signals before they ascend to conscious awareness.

In chronic neuropathic pain states, this descending inhibitory system becomes progressively underactive — partly because the constant barrage of abnormal pain signals exhausts its resources, and partly because the neuroplastic changes associated with chronic pain alter the responsiveness of these pathways. The result: the brain's own filter for pain signals becomes weaker precisely when it is needed most.

Nortriptyline at 10mg inhibits the reuptake transporters for serotonin and noradrenaline at synapses within this descending inhibitory pathway — prolonging the presence of both neurotransmitters in the synaptic cleft and thereby enhancing the activity of the inhibitory pathway they support. The brain's natural pain filter, amplified by nortriptyline, suppresses more of the incoming pain signal from the nerve injury — reducing what reaches conscious awareness.

Clinically, patients experience this as:

• Reduction in the overall intensity of chronic background pain
• Improved sleep (nortriptyline's mild sedative effect at low dose, combined with pain reduction, directly improves sleep quality)
• Reduction in the mood and anxiety component that frequently accompanies chronic nerve pain — not through an antidepressant effect per se, but through pain reduction itself

Why the Combination Outperforms Either Drug Alone

The clinical logic for combining these two drugs is not simply additive — it is mechanistically complementary:

Pregabalin reduces the abnormal signal being generated at the damaged nerve. But if the brain's descending filter remains weak, some of that signal still gets through and reaches painful intensity.

Nortriptyline strengthens the brain's filter — improving its ability to suppress pain signals that do arrive at the spinal cord. But if the peripheral nerve is still generating excessive abnormal signals, the filter is fighting a continuously overwhelming input.

Together — one reducing the input, one improving the filter — the combination achieves pain control at lower doses of each drug than would be required in monotherapy. This dose reduction is clinically important: pregabalin's dose-dependent sedation and dizziness, and nortriptyline's anticholinergic side effects, are both less pronounced at the doses used in combination than at the higher monotherapy doses that would be needed to achieve equivalent pain control with either drug alone.

This is the rationale cited in neurology prescribing practice and supported by clinical trial data comparing combination therapy to pregabalin or nortriptyline monotherapy in diabetic neuropathy and post-herpetic neuralgia.

Pregabalin and Nortriptyline Tablet Uses

1. Diabetic Peripheral Neuropathy — The Most Common Indication in India

Diabetic peripheral neuropathy (DPN) is the most prevalent single cause of neuropathic pain in India — a direct consequence of the country's diabetic epidemic, which affects an estimated 77 million adults. Sustained hyperglycaemia damages small sensory nerve fibres through multiple mechanisms: advanced glycation end-products alter nerve sheath proteins; oxidative stress damages the nerve vasculature; and metabolic changes in Schwann cells impair myelin maintenance.

The clinical result is a characteristic pattern — initially bilateral tingling and numbness beginning in the toes and soles of the feet ("stocking distribution"), progressing proximally as nerve damage worsens, and often producing intense burning or shooting pain at night. The nocturnal worsening is particularly disabling — it deprives patients of sleep, producing exhaustion and mood deterioration that compounds the pain experience.

DPN pain is driven precisely by the calcium channel overactivity and excitatory neurotransmitter excess that pregabalin targets — and the descending inhibitory pathway weakness that nortriptyline addresses. The combination is one of the most pharmacologically rational choices for DPN and is reflected in international and Indian diabetes neuropathy management guidelines as a recommended treatment option.

What patients notice: Most DPN patients on this combination report meaningful reduction in nocturnal burning within the first 1–2 weeks of treatment, with progressive improvement in daytime pain and tactile hypersensitivity over 4–8 weeks of consistent dosing.

2. Post-Herpetic Neuralgia — Nerve Pain After Shingles

Post-herpetic neuralgia (PHN) is one of the most debilitating chronic pain conditions seen in neurological and pain medicine practice — it occurs when varicella-zoster virus reactivation (shingles) causes lasting damage to sensory nerve fibres in the affected dermatome. Even after the shingles rash has fully healed — sometimes weeks to months later — the damaged nerve fibres in the skin continue generating persistent, often severe pain signals.

PHN pain has several characteristics that respond particularly well to this combination: spontaneous burning and shooting pain from voltage-gated calcium channel overactivity (pregabalin target), and allodynia — extreme sensitivity to touch in the affected area — which involves both peripheral sensitisation and central amplification (both pregabalin and nortriptyline targets through their complementary mechanisms).

PHN is more prevalent in elderly patients and in immunocompromised individuals, populations where the side effect profile of medications requires particular attention. The ability to achieve PHN pain control at lower individual doses by combining pregabalin and nortriptyline is a clinical advantage in these patients.

3. Fibromyalgia — Central Sensitisation and Widespread Pain

Fibromyalgia is characterised by widespread musculoskeletal pain, fatigue, cognitive difficulties ("fibro fog"), sleep disturbances, and heightened sensitivity to painful and non-painful stimuli across multiple body areas. The underlying pathophysiology is increasingly understood as central sensitisation — an abnormal amplification of pain signal processing within the central nervous system, where the pain-modulating circuits themselves have become dysregulated.

This central sensitisation mechanism maps directly onto what pregabalin and nortriptyline address together: pregabalin dampens the excitatory neurotransmitter excess driving central sensitisation, while nortriptyline strengthens the descending inhibitory pathways whose weakness contributes to the amplified pain perception.

Fibromyalgia predominantly affects women — with a female-to-male ratio of approximately 9:1 — and is often associated with sleep disruption and low mood, both of which nortriptyline addresses even at its low 10mg dose. The improvement in sleep quality that many fibromyalgia patients on this combination experience is frequently one of the earliest and most valued therapeutic benefits, preceding significant pain reduction by several weeks.

4. Sciatica and Lumbar Radiculopathy

Sciatica — pain radiating from the lower back through the buttock and down the leg along the path of the sciatic nerve — is one of the most common pain presentations in Indian general and orthopaedic practice. It is caused by compression or irritation of spinal nerve roots, most commonly from a herniated intervertebral disc, spinal stenosis, or degenerative disc disease.

The pain of sciatica has two components: a musculoskeletal component (back and buttock aching) that responds to NSAIDs, and a neuropathic radicular component (the shooting, burning, or electric-shock-like pain radiating down the leg) that does not respond to NSAIDs and requires neuro-targeted therapy.

Pregabalin and nortriptyline tablets specifically address the neuropathic radicular component — reducing the abnormal electrical signalling of the compressed nerve root and strengthening the descending inhibitory suppression of the amplified pain signals. In clinical practice, many sciatica patients receive both an NSAID (for the musculoskeletal component) and a pregabalin-based combination (for the radicular neuropathic component) as complementary parts of a multimodal pain management plan.

5. Chronic Neuropathic Pain — General Indication

Beyond specific diagnostic labels, neurologists frequently encounter patients with neuropathic pain that is difficult to categorise cleanly — chronic burning or shooting pain in the extremities, pain following nerve injuries from trauma or surgery, pain associated with multiple sclerosis or other neurological conditions, or idiopathic small fibre neuropathy. Where the pain has the characteristic qualities of nerve involvement — burning, electric, shooting, allodynia, or hypersensitivity — and has not responded to conventional analgesics, the pregabalin and nortriptyline combination provides a rational pharmacological intervention across all of these presentations.

6. Pain with Coexisting Anxiety and Sleep Disturbance

Chronic neuropathic pain and psychiatric comorbidities are closely linked. The same neural circuits disrupted by chronic pain — particularly the serotonin and noradrenaline pathways that nortriptyline targets — also regulate mood, anxiety, and sleep architecture. It is clinically very common for neuropathic pain patients to simultaneously experience sleep disruption (pain waking them at night, reduced sleep quality), elevated anxiety, and lowered mood — all of which amplify the pain experience in a reinforcing cycle.

Nortriptyline's actions on serotonin and noradrenaline at 10mg provide a gentle, sub-antidepressant modulation of these circuits that improves sleep quality and reduces the anxiety that heightens pain perception — without the pronounced anticholinergic and sedative side effects that nortriptyline's antidepressant-range doses (50–150mg) carry. This makes the combination particularly valuable for neuropathic pain patients in whom sleep disruption and mood impact are prominent components of the overall clinical picture.

Dosage — Clinical Guide by Patient Profile

Standard adult dosing (always follow the prescribing neurologist's specific instructions — doses are titrated to individual response and tolerability):

Important titration principle: Neuropathic pain medications — both pregabalin and nortriptyline — work better and are better tolerated when started at a lower dose and titrated upward. Neurologists typically start with a single tablet at night (taking advantage of both pregabalin's and nortriptyline's mild sedative effects at initiation to improve sleep immediately while the patient adjusts to the medication) and add a morning dose after 1–2 weeks if pain control is incomplete and tolerability is acceptable.

Dose adjustment in renal impairment: Pregabalin is renally excreted unchanged. In patients with reduced kidney function (reduced GFR), the pregabalin dose requires adjustment — which may mean this fixed-dose combination is not appropriate for moderate-to-severe renal impairment, where individualised dosing of each component separately is more appropriate. Your neurologist or nephrologist will guide this.

Elderly patients: Elderly patients are more susceptible to both pregabalin's dizziness and nortriptyline's anticholinergic effects. Starting at once-daily dosing and very gradual titration is standard practice. Falls risk from dizziness is a specific concern in the elderly — assess home environment and mobility before and during treatment.

Before or After Food? Timing and Practical Guidance

Pregabalin and nortriptyline tablets can be taken with or without food — food does not significantly alter the absorption of either active ingredient.

However, for practical clinical reasons, taking with food is generally preferred:

• Reduces nausea — particularly during the first week of treatment when patients are adjusting to both drugs, taking with food reduces the nausea that some patients experience from nortriptyline's anticholinergic activity
• Reduces dizziness — food slows gastric emptying, moderating the rate of absorption and blunting the early-dose peak concentration that causes dizziness in some pregabalin-sensitive patients

Night-time dosing strategy: For the first tablet of the day (initiated as night-only dosing), taking with or just after dinner is practical — the mild sedative effect of both components can aid sleep onset, and the peak plasma levels during sleep minimise the functional impact of any dizziness or sedation during the active day.

When a morning dose is added, taking it with breakfast minimises the impact of any residual morning sedation on daytime activities.

Side Effects of Pregabalin and Nortriptyline Tablets

This combination has a well-characterised side effect profile. The lower doses used in the FDC format typically produce fewer and milder side effects than monotherapy at higher doses — but awareness of the following is important for safe use:

Common (particularly in the first 1–4 weeks of treatment):

• Dizziness and light-headedness — The most common pregabalin side effect. Usually most pronounced in the first 1–2 weeks and diminishes as tolerance develops. Sit up slowly from lying down, avoid sudden position changes. Risk of falls — particularly in elderly patients.
• Drowsiness and sedation — Attributable to both components. Most pronounced at initiation and with dose escalation. Useful for sleep; problematic for daytime activities. Typically reduces significantly after the first 2 weeks. Avoid driving until individual tolerance is established.
• Dry mouth — Nortriptyline's anticholinergic effect on salivary glands. Managed with frequent sips of water, sugar-free lozenges, or gum. Usually mild at 10mg.
• Weight gain — Pregabalin is associated with appetite increase and weight gain with long-term use, particularly at higher doses. Dietary awareness and physical activity maintenance help mitigate this.
• Peripheral oedema (ankle swelling) — Pregabalin causes fluid retention in some patients, manifesting as mild ankle or foot swelling. Usually mild; report to your neurologist if it worsens.
• Blurred vision — Nortriptyline's anticholinergic effect on the ciliary muscle of the eye. Usually mild and transient at 10mg.

Less common but clinically relevant:

• Constipation — Nortriptyline's anticholinergic reduction of GI motility. Adequate fluid and fibre intake; discuss with your doctor if severe.
• Urinary hesitancy or retention — Nortriptyline's anticholinergic effect on bladder tone. More relevant in elderly men with benign prostatic hyperplasia (BPH).
• Cognitive effects ("brain fog") — Pregabalin at higher doses can cause concentration difficulty and short-term memory impact in some patients. Usually mild at 75mg; report if it significantly affects daily function.
• Euphoria — Pregabalin carries a small risk of euphoric effect, which has driven its classification as a Schedule H drug in India. It should not be self-administered at doses beyond what is prescribed or for longer than the prescribed course.
• Cardiac arrhythmia — Nortriptyline's cardiovascular effects (QT interval prolongation) are negligible at 10mg but relevant if a patient has pre-existing cardiac conduction disease. Discuss with your cardiologist if cardiac conditions are present.

What this combination does NOT cause at prescribed doses:

• Opioid-type dependence or withdrawal (pregabalin Schedule H classification is for misuse potential, not opioid-type dependence)
• Hepatotoxicity — neither drug is significantly hepatotoxic at these doses
• The full anticholinergic syndrome associated with antidepressant-range nortriptyline (50–150mg)

Important Precautions and Contraindications

Driving and machinery: Do not drive or operate heavy machinery until you know how this combination affects your alertness — particularly during the first 2–4 weeks of treatment and after any dose increase.

Alcohol: Significantly amplifies the sedative effects of both pregabalin and nortriptyline. Avoid alcohol during treatment.

Renal impairment: Pregabalin dose requires reduction in renal impairment. This fixed-dose combination should be used with caution and under close medical supervision in patients with CKD. Your neurologist may switch to individually dosed components to allow appropriate pregabalin dose adjustment.

Pregnancy: Both pregabalin (Category C) and nortriptyline carry potential fetal risks. Avoid unless the clinical benefit clearly outweighs the risk — discuss with your neurologist and obstetrician.

Breastfeeding: Both drugs transfer into breast milk. Avoid during breastfeeding unless specifically directed by a physician with full clinical context.

Cardiac disease: Nortriptyline, even at low doses, has cardiac effects relevant in patients with arrhythmias, recent MI, or QT prolongation syndromes. Discuss with your cardiologist.

History of seizures: Pregabalin can increase seizure threshold — paradoxically, abrupt discontinuation can lower it. Do not stop this medication suddenly; taper under neurologist guidance.

Glaucoma: Nortriptyline's anticholinergic effect can worsen narrow-angle glaucoma. Patients with glaucoma should inform their ophthalmologist and prescribing neurologist.

Monoamine oxidase inhibitors (MAOIs): Nortriptyline is contraindicated in patients currently taking or who have taken an MAOI within the past 14 days — the combination can cause severe serotonin syndrome.

Drug Interactions — What Your Neurologist Needs to Know

Other CNS depressants (benzodiazepines, opioids, sedating antihistamines, alcohol): Additive CNS depression — significantly increased sedation and falls risk. Report all psychoactive medications to your prescribing neurologist.

MAOIs: Absolutely contraindicated with nortriptyline — risk of fatal serotonergic crisis.

Serotonergic medications (SSRIs, SNRIs, tramadol, certain triptans): Risk of serotonin syndrome with concurrent nortriptyline use. This combination requires careful clinical assessment.

Anticholinergic medications (bladder agents, anti-Parkinson drugs, antispasmodics): Additive anticholinergic effects with nortriptyline — worsen dry mouth, constipation, urinary retention, and cognitive effects.

Antihypertensives: Nortriptyline can alter the response to certain antihypertensives. BP monitoring is advisable when starting treatment in hypertensive patients.

Metformin and diabetes medications: Pregabalin can cause weight gain and may affect blood glucose control in diabetic patients — monitor HbA1c and fasting glucose during long-term treatment.

Angiotensin-converting enzyme inhibitors (ACE inhibitors): Pregabalin combined with ACE inhibitors may increase the risk of pregabalin-related oedema.

Long-Term Use — What Patients Need to Know

Neuropathic pain from diabetic neuropathy, post-herpetic neuralgia, and fibromyalgia is frequently a chronic, long-term condition. Many patients require ongoing pharmacological management for months to years. Here is what long-term use of this combination involves:

Periodic reassessment: Your neurologist should periodically (typically every 3–6 months) reassess whether the current dose is still appropriate — considering pain control achieved, side effect burden, and whether dose escalation or reduction is warranted based on disease progression or improvement.

Weight monitoring: Pregabalin-associated weight gain can accumulate over months of treatment. Regular weight monitoring and dietary awareness are advisable for long-term patients.

Renal function monitoring: In diabetic patients (who are at elevated CKD risk), regular renal function assessment ensures the pregabalin component remains at an appropriate dose as kidney function may change over time.

Do not stop suddenly: Abrupt cessation of pregabalin can cause withdrawal symptoms — insomnia, nausea, headache, diarrhoea, and in rare cases, seizure. Always taper under neurologist guidance.

Does it cause dependence? Pregabalin has been associated with misuse, particularly in patients with a history of substance dependence, and is classified as a Schedule H drug in India. At prescribed therapeutic doses in patients without a prior history of substance use disorder, the risk of problematic use is low but not absent. Report any urge to take more medication than prescribed to your neurologist.

Pregabalin vs Nortriptyline vs Combination — The Clinical Comparison

The practical conclusion: the combination achieves better clinical outcomes at lower individual doses of each drug — with a better tolerability profile than either drug at the monotherapy doses that would be needed to achieve equivalent pain control.

Conclusion

Pregabalin and nortriptyline tablets represent one of the most pharmacologically rational and clinically validated approaches to neuropathic pain management available in India today — addressing the two most important mechanisms of chronic nerve pain in a single, convenient fixed-dose tablet at doses that balance therapeutic efficacy with manageable side effects. For the millions of Indian patients with diabetic peripheral neuropathy, post-herpetic neuralgia, fibromyalgia, sciatica, and other chronic nerve pain conditions, this combination offers what standard analgesics cannot: treatment targeted at the neural mechanisms actually generating and amplifying their pain.

For patients, understanding how these two drugs complement each other, what to expect from treatment initiation, and how to manage the early side effects that typically resolve within weeks makes the difference between a successful long-term therapy and premature abandonment of an effective treatment. For neurologists, this guide provides a complete clinical reference for patient counselling, indication selection, dosage titration, and safety monitoring across the full spectrum of neuropathic pain presentations.

To explore the complete product composition, formulation quality standards, and manufacturing details for pregabalin and nortriptyline tablets manufactured by Delwis Healthcare, visit the product page. To explore the full neuro-psychiatric range of tablets manufactured at our WHO-GMP certified Ahmedabad facility, visit the Delwis Healthcare neuro-psychiatric portfolio.

Frequently Asked Questions

Q: What is pregabalin and nortriptyline tablet used for?

Pregabalin and nortriptyline tablets are used for chronic neuropathic pain — nerve pain conditions including diabetic peripheral neuropathy, post-herpetic neuralgia following shingles, fibromyalgia, sciatica, and lumbar radiculopathy. They are not effective for conventional musculoskeletal or inflammatory pain and should not be used as a substitute for standard analgesics in those conditions.

Q: How do pregabalin and nortriptyline work together for nerve pain?

Pregabalin reduces the abnormal electrical hyperactivity of damaged nerve fibres by binding to calcium channels and reducing the release of pain-amplifying neurotransmitters. Nortriptyline at low dose strengthens the brain's own descending pain-suppression pathway by prolonging serotonin and noradrenaline at inhibitory synapses. Together — one reducing the pain signal being generated, one improving the brain's ability to filter it — the combination achieves superior pain control at lower individual doses than either drug alone.

Q: What are the side effects of pregabalin and nortriptyline tablets?

The most common side effects are dizziness, drowsiness, dry mouth, and mild weight gain — particularly in the first 2–4 weeks of treatment. Most side effects are dose-dependent and tend to reduce as the body adjusts. Peripheral oedema (ankle swelling), constipation, blurred vision, and cognitive effects are less common. Severe side effects are rare at the doses used in this combination. Report any unusual symptoms to your neurologist.

Q: How long does pregabalin and nortriptyline take to work?

Initial improvement — particularly in sleep and nocturnal burning pain — typically begins within the first 1–2 weeks. Full analgesic benefit, particularly for nortriptyline's descending pathway effects, builds over 4–8 weeks. Assessment of treatment efficacy should not be made before 4 weeks of consistent dosing at therapeutic dose.

Q: Is pregabalin and nortriptyline tablet safe for long-term use?

Yes, with appropriate monitoring. Both drugs are used long-term in neuropathic pain management. Periodic neurologist review — typically every 3–6 months — should assess pain control, side effects, weight, and renal function (particularly in diabetic patients). Do not discontinue suddenly — taper under neurologist guidance.

Q: Can this tablet be taken by elderly patients?

Yes, with extra caution. Elderly patients are more susceptible to dizziness (falls risk), anticholinergic effects (urinary retention, cognitive effects), and sedation. Starting with single-tablet night-only dosing and very gradual titration is standard for elderly patients. Falls assessment and home safety review are advisable before and during treatment.

Q: Is nortriptyline 10mg good for diabetic neuropathy?

At 10mg, nortriptyline contributes meaningfully to neuropathic pain control in diabetic neuropathy through its effect on descending inhibitory pathways — but this low dose alone is unlikely to be sufficient for most patients as monotherapy. In the combination with pregabalin 75mg, nortriptyline's complementary mechanism provides clinically significant additive pain reduction that is well-documented in diabetic neuropathy clinical trials.

Q: Does pregabalin and nortriptyline cause weight gain or drowsiness?

Pregabalin is associated with both weight gain (appetite stimulation and fluid retention) and drowsiness — both dose-dependent and more significant with higher-dose monotherapy. In this combination at 75mg pregabalin + 10mg nortriptyline, both effects are generally milder than seen with pregabalin monotherapy at 150–300mg. Drowsiness typically reduces significantly after the first 2–4 weeks. Weight should be monitored with long-term use.

Q: What is the difference between pregabalin and nortriptyline tablet vs pregabalin methylcobalamin and nortriptyline tablet?

Some formulations of this combination also include methylcobalamin — an active form of vitamin B12 that supports nerve myelin repair and regeneration. This three-way combination is particularly relevant in diabetic neuropathy and nutritional deficiency neuropathies where B12 deficiency co-exists with the neuropathic pain. The pregabalin + nortriptyline two-drug combination addresses pain signal generation and amplification; adding methylcobalamin targets the structural nerve repair dimension. Your neurologist will select the appropriate formulation based on your specific clinical profile.

This article is written for informational and educational purposes only. It does not constitute medical advice, a diagnosis, or a treatment recommendation. All neuropathic pain management decisions — including drug selection, dose titration, and duration of therapy — must be made by a qualified neurologist or physician based on individual clinical assessment, comorbidities, concurrent medications, and laboratory parameters.